Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers Halt Spread of HIV with RNAi

11.08.2008
Using a novel method to deliver small molecules called siRNAs into T cells, researchers dramatically suppressed HIV in the first-ever animal model that mirrors progression of the disease in humans. The siRNAs knocked down three key genes and kept the infection from spreading in mice containing human immune cells infected with the virus.

Hopes languished last September when a promising candidate HIV vaccine failed to work. Despite this setback, many researchers still believe immunization is possible, and a new study suggests they’re correct—at least at the cellular level.

Working in mice infected with HIV, a team used a method called RNA interference to knock down three genes in T cells, protecting them from the virus. This method seemed to prevent HIV from jumping between cells in the mice.

“For the first time, we’ve used RNAi to dramatically suppress HIV infection in an organism,” says corresponding author Premlata Shankar, who conducted the work while she was a junior investigator at the Harvard Medical School-affiliated Immune Disease Institute and an assistant professor at Harvard Medical School. Shankar is now a professor at Texas Tech University Health Sciences Center in El Paso.

... more about:
»HIV »HIV vaccine »Harvard »RNA »RNAi »Shankar »T cells »Virus »immunization »siRNA

Although labs must verify the findings in other animal models before attempting clinical trials, this method—published online Aug. 7 in Cell—may eventually supplement or replace the harsh drug cocktails currently prescribed to patients with HIV, reducing the side effects of treatment.

When the Nobel Prize in Physiology or Medicine was awarded in 2006 for the discovery of RNAi, the judges speculated that it might “lead to novel therapies in the future.” Researchers hoped to flood specific cells in patients with short interfering RNAs (siRNAs), molecules that silence genes by disrupting the protein templates they produce. But scientists weren’t sure how to deliver the siRNAs exclusively into relevant cell types within an organism.

In collaboration with Sang-Kyung Lee of Hanyang University, Shankar’s lab overcame this obstacle, delivering siRNAs directly into T cells, which are targeted by HIV. The team used an apparatus analogous to a truck equipped with GPS and a trailer hitch to haul the siRNAs to their destination. The truck—in this case, a single-chain antibody developed by Georg Fey of the University of Erlangen in Germany—homed to a protein found exclusively on the surface of T cells. The trailer hitch—an oligo-9-arginine—pulled siRNAs along for the ride.

This new antibody delivery vehicle lends itself to mass production in a dish. The team built thousands of these carriers for use in experiments, loading them with siRNAs targeting three key genes. One encodes a human protein called CCR5, which dots the surface of T cells and allows HIV to gain entry. The others encode proteins produced by the virus within cells upon infection.

Harvard Medical School postdoctoral researcher and first author Priti Kumar mixed the siRNAs with the antibody carriers and injected them into the veins of mice that harbor human T cells rather than their own. These mice serve as an animal model of HIV. After being infected with the virus, the mice mirror progression of the disease in humans.

Developed by study co-authors Leonard Shultz of the Jackson Laboratory and Dale Greiner of the University of Massachusetts, these mice lack their own immune systems, so they tolerate tissue from other species. The team injected the mice with human blood stem cells, which divided time and again, building a human immune system in their hosts. When infected with HIV, the synthetic immune system seemed to respond as it would in humans, since T cell levels followed the same pattern in both species.

Kumar’s siRNAs halted T cell destruction in the mice, essentially stopping the virus in its tracks.

“Both prophylactic and therapeutic regimens proved successful,” said Kumar. “Apparently, the siRNAs kept HIV from entering most T cells and kept it from replicating when it managed to slip inside.”

Kumar and Shankar caution that labs need to confirm the findings in other animals, tweak the dosage, and tinker with the siRNA delivery vehicle before attempting clinical trials. In addition, the molecules degrade with time, so periodic shots may be necessary to maintain cellular immunity, precluding large-scale vaccination.

“I’m not saying we’ve developed tomorrow’s therapy, but this is a major step forward,” says Shankar. “We’ve used a small animal model for HIV and proven that RNAi works in that model.”

John Rossi, a pioneer in RNA-based therapeutics who was not part of the study, hopes labs will use the new animal model to compare the side effects of potential and existing therapeutic regimens.

“The number one problem with the current antiretroviral drug regimens is toxicity,” says Rossi, a professor at the Beckman Research Institute of the City of Hope. He wonders if siRNAs will eventually enable doctors to lower the doses of existing drugs in patients. Perhaps siRNAs will one day supplement or replace harsh antiretrovirals.

“Overall, I see this work as an exciting proof of principle,” says Rossi. “This is a strategy that can be developed for clinical applications in humans.”

This research is supported by the National Institutes of Health, the Korea Ministry of Education and Science Technology, and the Center for AIDS Research at Harvard.

Alyssa Kneller | Newswise Science News
Further information:
http://hms.harvard.edu

Further reports about: HIV HIV vaccine Harvard RNA RNAi Shankar T cells Virus immunization siRNA

More articles from Life Sciences:

nachricht Polymers Based on Boron?
18.01.2018 | Julius-Maximilians-Universität Würzburg

nachricht Bioengineered soft microfibers improve T-cell production
18.01.2018 | Columbia University School of Engineering and Applied Science

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

Im Focus: A thermometer for the oceans

Measurement of noble gases in Antarctic ice cores

The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

World’s oldest known oxygen oasis discovered

18.01.2018 | Earth Sciences

Uncovering decades of questionable investments

18.01.2018 | Business and Finance

Novel chip-based gene expression tool analyzes RNA quickly and accurately

18.01.2018 | Medical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>